Serum Institute of India is the vaccine producer that will invest 50 million pounds ($68.24 million) in Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca, the British cell therapy firm said.

• United Spirits Gets Relief As FSSAI Revokes Two Orders
• Zydus Gets USFDA Nod For Ascorbic Acid Injection
• Puravankara Rises After Rs 175 Crore Chennai Hotel Order
• Zodiac Energy Gains After Winning UP Solar Plant Order
• Delhi Master Plan 2047 Notified With Major Overhaul

The proceeds of the transaction will be used to fund the development of the fallow area at Oxbox, the group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023.